Leadership

Mr. Stephen H. Willard has been Chief Executive Officer and member of the Board of Directors of Flamel Technologies SA since 2001. Prior to being asked to serve as CEO by the Board of Directors in June of 2005, Mr. Willard was the Company’s Chief Financial Officer and General Counsel. Prior joining the Company in August 2000, Mr. Willard was Vice President of Biovail Corporation (now Valeant Pharmaceuticals International, Inc.; NYSE/TSX: VRX). He previously served as Associate Director of Resolutions of the Federal Deposit Insurance Corporation (“FDIC”) of the USA. Mr. Willard worked also as an investment banker at Credit Suisse First Boston and as an attorney with Gibson, Dunn & Crutcher LLP and Shearman & Sterling LLP. He is a member of the Board of Directors of E-Trade Financial Corporation (NASDAQ: ETFC) since April 2005. Mr. Willard is a Juris Doctorate (J.D.) of Yale Law School (USA) and received a Bachelor of Arts degree from Williams College (USA).

Dr. Rafael Jorda has been Executive Vice President and Chief Operating Officer of Flamel Technologies SA since 2005. He joined the Company in early 1991. Previously Mr. Jorda worked 14 years as a research and development scientist on controlled-released and biopolymers at Rhone-Poulenc. He is specialized in chemical engineering and in the structure-property relationships of materials. Mr Jorda is a graduate of “Ecole Nationale Supérieure de Chimie de Lyon” (France).

Mrs. Sian Crouzet has been Principal Financial Officer of Flamel Technologies SA since March 2008. She previously worked as Financial Controller France for McCormick & Company Inc. Mrs. Crouzet also worked five years as an external auditor with Ernst and Young (France and UK). She is a UK Chartered Accountant and a graduate of Bradford University (UK).

Mr. Yves Bourboulou is Director of Manufacturing Facility. He worked previously as Plant Manager at Pharmacia and Fresenius Kabi. Mr. Bourboulou previously held various senior positions including Quality Assurance Director and Chief Pharmacist Officer (CPO) in the Pharmaceutical Industry. He has more than 20 years experience in pharmaceutical production, quality and development.

Mr. Nigel McWilliam is Vice President of Business Development. He joined the Company in its Washington office in August 2005. Mr. McWilliam spent 20 years with Dow Corning Corporation’s Health Care Businesses in commercial positions in Europe and the U.S. He also had various senior positions as President of Leiras Inc., the U.S. subsidiary of a Finnish pharmaceutical company (now part of Bayer-Schering, AG), as CEO of Veos Ltd., and as Senior V.P. Business Development at SkyePharma. Mr. McWilliam has a Bachelor degree in Science from the University of Dundee.

Dr. Jean Chatellier is Vice President of Alliance Management. He joined Flamel Technologies in October 2010. He served previously as Director of Business Development at Micromet AG (Nasdaq: MITI) and added other business development activities for Crucell (Nasdaq: CRXL) and Viropro Inc. (PINK: VPRO). He also was the founder and CEO of Imaxio SA, and was ex-CEO and liquidator of Aptanomics SA. He obtained a binational Ph.D. in Protein Engineering from Strasbourg, France and Montréal, Canada. He also performed post-doctoral research with Sir Allan Fersht and Sir Greg Winter at the Center for Protein Engineering of the Medical Research Council, Cambridge UK.

Mr. Christian Kalita has been Chief Pharmaceutical Officer, Director of Quality and Regulatory Affairs of Flamel Technologies SA since 2005. He worked previously at SkyePharma as Director of Quality for Europe. Mr. Kalita also worked 10 years for Merck Lipha and Merck generics in different roles as Chief Pharmaceutical Officer, Head of Quality Control Management and Head of Industrial Affairs.

Dr. Rémi Meyrueix is Director of Medusa Platform of Flamel Technologies SA. He joined the Company in early 1991 after having spent 8 years at Rhone Poulenc. Mr. Meyrueix holds an engineer degree and a Ph.D. in physics from the Polytechnic Institute of Grenoble (France).

Dr. Catherine Castan is Director of Micropump Platform (Oral Drugs) and Intellectual Property of Flamel Technologies SA. She joined the Company in 1992 after having spent 4 years at Sanofi Recherche. Mrs. Castan is a graduate of “Ecole Nationale Supérieure de Chimie de Montpellier” and has a Ph.D. in polymer chemistry, applied in drug delivery.

Dr. You-Ping Chan is Director of Chemistry and Analysis of Flamel Technologies SA. He joined the Company in 1992 as a researcher in polymer science after post-doctoral research at the Massachusetts Institute of Technology (USA). He received his Ph.D. in Chemistry from Strasbourg, France.

Dr. Roger Kravtzoff is Director of Preclinical and Clinical Development of Flamel Technologies SA. He joined the Company in June 2002. Previously, Mr. Kravtzoff worked as Project Director at Biovector Therapeutics. He also had senior scientist positions at Novacell and the “Centre Regional de Transfusion Sanguine”. Mr. Kravtzoff obtained a Ph.D. in Biochemistry from Tours, France.

Mr. Charles Mosseri-Marlio is Director of Strategic Planning and Investor Relations of Flamel Technologies SA, having previously served as Associate General Counsel. He joined the Company in 2004 after working as a portfolio manager of Baldwin Brothers Inc., a U.S. Investment Advisory firm. Mr. Mosseri-Marlio received his JD from the University of Colorado (USA).